Vaccines for preventing influenza in healthy adults
- 7 July 2010
- reference entry
- Published by Wiley
- No. 7,p. CD001269
- https://doi.org/10.1002/14651858.cd001269.pub4
Abstract
Background Different types of influenza vaccines are currently produced worldwide. Healthy adults are presently targeted mainly in North America. Objectives Identify, retrieve and assess all studies evaluating the effects of vaccines against influenza in healthy adults. Search strategy We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2010, issue 2), MEDLINE (January 1966 to June 2010) and EMBASE (1990 to June 2010). Selection criteria Randomised controlled trials (RCTs) or quasi-RCTs comparing influenza vaccineswith placebo or no intervention in naturally-occurring influenza in healthy individuals aged 16 to 65 years. We also included comparative studies assessing serious and rare harms. Data collection and analysis Two review authors independently assessed trial quality and extracted data. Main results We included 50 reports. Forty (59 sub-studies) were clinical trials of over 70,000 people. Eight were comparative non-RCTs and assessed serious harms. Two were reports of harms which could not be introduced in the data analysis. In the relatively uncommon circumstance of vaccine matching the viral circulating strain and high circulation, 4% of unvaccinated people versus 1% of vaccinated people developed influenza symptoms (risk difference (RD) 3%, 95% confidence interval (CI) 2% to 5%). The corresponding figures for poor vaccine matching were 2% and 1% (RD 1, 95% CI 0% to 3%). These differences were not likely to be due to chance. Vaccination had a modest effect on time off work and had no effect on hospital admissions or complication rates. Inactivated vaccines caused local harms and an estimated 1.6 additional cases of Guillain-Barre Syndrome per million vaccinations. The harms evidence base is limited. Authors' conclusions Influenza vaccines have a modest effect in reducing influenza symptoms and working days lost. There is no evidence that they affect complications, such as pneumonia, or transmission.Keywords
This publication has 133 references indexed in Scilit:
- Efficacy of Inactivated Split‐Virus Influenza Vaccine against Culture‐Confirmed Influenza in Healthy Adults: A Prospective, Randomized, Placebo‐Controlled TrialThe Journal of Infectious Diseases, 2009
- Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete exampleBMC Infectious Diseases, 2009
- Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 SeasonThe Journal of Infectious Diseases, 2009
- Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analysesVirus Research, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Vaccinations and the Risk of Relapse in Multiple SclerosisNew England Journal of Medicine, 2001
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adultsJournal of Medical Virology, 1981
- Clinical and serologic effects of live attenuated serum inhibitor‐resistant influenza B vaccine in seronegative adultsJournal of Medical Virology, 1977